TY - JOUR
T1 - Oncostatin-M-Reactive Pericytes Aggravate Blood–Brain Barrier Dysfunction by Activating JAK/STAT3 Signaling In Vitro
AU - Takata, Fuyuko
AU - Dohgu, Shinya
AU - Sakaguchi, Shinya
AU - Sakai, Kenta
AU - Yamanaka, Gaku
AU - Iwao, Takuro
AU - Matsumoto, Junichi
AU - Kimura, Ikuya
AU - Sezaki, Yume
AU - Tanaka, Yoshie
AU - Yamauchi, Atsushi
AU - Kataoka, Yasufumi
N1 - Funding Information:
The authors thank Ms. Kana Hashiguchi, Ms. Miho Yasunaga, Mr. Kazuki Tominaga, Ms. Yuko Yoshinaga, Ms. Ayako Doi, Ms. Rika Ikeda, Mr. Kazuki Kanemura, and Ms. Moe Hirano for technical assistance. We are also immensely grateful to Dr. Mária A Deli and Dr. Fruzsina R. Walter in Biological Research Centre, Hungarian Academy of Sciences for their comments on an earlier version of the manuscript. This work was supported in part by a Grants-in-Aid for Scientific Research to F.T. 18K06712, S.D. 16K08566, and Y.K. 16K08429, from the Japan Society for the Promotion of Science. The work was also supported by funds (to F.T.) from Fukuoka University Program to support the research activities of female researchers, and funds (to F.T.) 181044, (to F.T. and S.D.) 167111, (to Y.K.) 166003, (to S.D.) 166005, and (to A.Y.) 166006 from the Central Research Institute of Fukuoka University. The authors thank Dr. Bronwen Gardner (Edanz Group: www.edanzediting.com/ac) for editing this draft of the manuscript. The authors declare that they have no conflicts of interest with the contents of this article.
Funding Information:
The authors thank Ms. Kana Hashiguchi, Ms. Miho Yasunaga, Mr. Kazuki Tominaga, Ms. Yuko Yoshinaga, Ms. Ayako Doi, Ms. Rika Ikeda, Mr. Kazuki Kanemura, and Ms. Moe Hirano for technical assistance. We are also immensely grateful to Dr. Mária A Deli and Dr. Fruzsina R. Walter in Biological Research Centre, Hungarian Academy of Sciences for their comments on an earlier version of the manuscript. This work was supported in part by a Grants-in-Aid for Scientific Research to F.T. 18K06712, S.D. 16K08566, and Y.K. 16K08429, from the Japan Society for the Promotion of Science . The work was also supported by funds (to F.T.) from Fukuoka University Program to support the research activities of female researchers, and funds (to F.T.) 181044, (to F.T. and S.D.) 167111, (to Y.K.) 166003, (to S.D.) 166005, and (to A.Y.) 166006 from the Central Research Institute of Fukuoka University. The authors thank Dr. Bronwen Gardner (Edanz Group: www.edanzediting.com/ac ) for editing this draft of the manuscript. The authors declare that they have no conflicts of interest with the contents of this article.
Publisher Copyright:
© 2019 IBRO
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Oncostatin M (OSM) is a cytokine of the interleukin (IL)-6 family members. It induces blood–brain barrier (BBB) dysfunction by activating Janus-activated kinase (JAK) and signal transducer and activator of transcription (STAT) 3 pathways in brain endothelial cells. Brain pericytes located around microvessels are one of the BBB constituents. Pericytes work as a boundary surface between the blood circulation and brain parenchyma, and their functions are altered under pathophysiological conditions, leading to BBB dysregulation. However, it remains unknown whether pericytes are associated with OSM-induced BBB dysfunction. We demonstrated that pericyte exposure to OSM (100 ng/mL) elevated phosphorylation of STAT3, a main OSM signaling pathway, and that pericytes expressed OSM receptors (OSMRs) including OSMRβ and glycoprotein 130. These results suggest that pericytes are able to respond to OSM. To determine the effects of OSM-reactive pericytes on BBB functions, rat brain endothelial cell (RBEC) monolayers were cultured with OSM-treated pericytes. The presence of pericytes exposed to 100 ng/mL of OSM for 48 h aggravated both the elevated permeability to sodium fluorescein and the lowered transendothelial electrical resistance which were induced by OSM in RBECs. This OSM-reactive pericyte-induced aggravation of lowered RBEC barrier function was reversed by ruxolitinib, a JAK inhibitor. These findings suggest that activated JAK/STAT3 signaling in pericytes contributes to OSM-produced BBB breakdown. Thus, OSM-reactive pericytes may have to be considered a characteristic machinery in the formation and progression of BBB breakdown under pathological conditions associated with increased OSM levels.
AB - Oncostatin M (OSM) is a cytokine of the interleukin (IL)-6 family members. It induces blood–brain barrier (BBB) dysfunction by activating Janus-activated kinase (JAK) and signal transducer and activator of transcription (STAT) 3 pathways in brain endothelial cells. Brain pericytes located around microvessels are one of the BBB constituents. Pericytes work as a boundary surface between the blood circulation and brain parenchyma, and their functions are altered under pathophysiological conditions, leading to BBB dysregulation. However, it remains unknown whether pericytes are associated with OSM-induced BBB dysfunction. We demonstrated that pericyte exposure to OSM (100 ng/mL) elevated phosphorylation of STAT3, a main OSM signaling pathway, and that pericytes expressed OSM receptors (OSMRs) including OSMRβ and glycoprotein 130. These results suggest that pericytes are able to respond to OSM. To determine the effects of OSM-reactive pericytes on BBB functions, rat brain endothelial cell (RBEC) monolayers were cultured with OSM-treated pericytes. The presence of pericytes exposed to 100 ng/mL of OSM for 48 h aggravated both the elevated permeability to sodium fluorescein and the lowered transendothelial electrical resistance which were induced by OSM in RBECs. This OSM-reactive pericyte-induced aggravation of lowered RBEC barrier function was reversed by ruxolitinib, a JAK inhibitor. These findings suggest that activated JAK/STAT3 signaling in pericytes contributes to OSM-produced BBB breakdown. Thus, OSM-reactive pericytes may have to be considered a characteristic machinery in the formation and progression of BBB breakdown under pathological conditions associated with increased OSM levels.
UR - http://www.scopus.com/inward/record.url?scp=85074773394&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074773394&partnerID=8YFLogxK
U2 - 10.1016/j.neuroscience.2019.10.014
DO - 10.1016/j.neuroscience.2019.10.014
M3 - Article
C2 - 31705893
AN - SCOPUS:85074773394
VL - 422
SP - 12
EP - 20
JO - Neuroscience
JF - Neuroscience
SN - 0306-4522
ER -